Bellerophon Therapeutics   Report issue

For profit Phase 2 Phase 3
Founded: Warren NJ United States (2009)
Status: No NME R&D (2009)

Organization Overview

First Clinical Trial
2012
NCT01457781
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Acting Chief Medical Officer | Bellerophon | Bellerophon Pulse Technologies | Bellerophon Therapeutics | Bellerophon Therapeutics (consultant) | Bellerophon Therapuetics

Active Ingredients

Drugs in Phase 3 Trials (1)

nitric oxide (inomax) (13 trials)

Drugs in Phase 2 Trials (3)

nitrogen (1 trial)

nitrous oxide (1 trial)

oxygen (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Familial Primary Pulmonary Hypertension (Phase 3)

Fibrosis (Phase 2)

Hypertension (Phase 3)

Hypertension, Pulmonary (Phase 2)

Hypoxia (Phase 2)

Idiopathic Pulmonary Fibrosis (Phase 1)

Lung Diseases (Phase 2)

Lung Diseases, Obstructive (Phase 2)

Pulmonary Disease, Chronic Obstructive (Phase 2)

Pulmonary Fibrosis (Phase 2)

Respiratory Aspiration (Phase 2)

Respiratory Insufficiency (Phase 2)

Sarcoidosis (Phase 2)

Sarcoidosis, Pulmonary (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 14
  • # of Trial APIs: 4